||Rapid Review Complete
||For the treatment of adults with advanced renal cell carcinoma, in combination with pembrolizumab, as first-line treatment
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lenvatinib in combination with pembrolizumab for first-line treatment of patients with advanced RCC compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.